This finding is highly significant, as it suggests that ruxolitinib has the potential for drug repurposing.
← all excerpts
Bioinformatics and experimental approaches identify NME8 as a promoter of the metastasis of renal cell carcinoma by activating the JAK/STAT signaling pathway.
1
—
—